Fosifloxuridine nafalbenamide clinical trials
Also written NUC-3373.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses fosifloxuridine nafalbenamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
NuCana plc (3) · University of Oxford (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses fosifloxuridine nafalbenamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursTerminatedPhase 1/2NuCana plcNCT05714553Written as Fosifloxuridine Nafalbenamide
- A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal CancerTerminatedPhase 2NuCana plcNCT05678257Written as Fosifloxuridine Nafalbenamide
- A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer TreatmentCompletedPhase 1/2NuCana plcNCT03428958Written as NUC-3373 + leucovorin
- NUC-3373 in Advanced Solid TumoursCompletedPhase 1University of OxfordNCT02723240Written as NUC-3373
Codes
What other systems call fosifloxuridine nafalbenamide · ClinicalTrials.gg INT014951
- UNII (FDA) 4YO6QT3SZ9FOSIFLOXURIDINE NAFALBENAMIDEOne source FDA
- NCI Thesaurus C156680Fosifloxuridine NafalbenamideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4YO6QT3SZ9 | FOSIFLOXURIDINE NAFALBENAMIDE | One source FDA |
| NCI Thesaurus | C156680 | Fosifloxuridine Nafalbenamide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.